WuXi Biologics, a wholly owned subsidiary of WuXi AppTec, and Prima BioMed, an immuno-oncology company, announced on March 2, 2016 that through a strategic supply partnership, Prima s immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi s cGMP facility in ChinOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.